04 Mar Monoclonal Antibody Idarucizumab Reverses Anticoagulant Effect of Dabigatran In Patients With Brain Bleed
MedicalResearch.com Interview with:
Dr. Richard Bernstein
Richard A. Bernstein MD, PhD
Director, Northwestern Stroke Program
Professor of Neurology
Feinberg School of Medicine of Northwestern University
Medical Research: What is the background for this study?
Dr. Bernstein: Patients on blood thinners, including dabigatran, have an increased risk of bleeding including in the brain. We believe that reversing the blood thinning effects of dabigatran in the setting of bleeding might improve outcome by helping the bleeding to stop.
Medical Research: What are the main findings?
Dr. Bernstein: We found that in 18 patients taking dabigatran with intracranial bleeding, Idarucizumab completely and nearly instantaneously reversed the blood thinning effect of dabigatran.
Medical Research: What should clinicians and patients take away from your report?
Dr. Bernstein: Patients taking dabigatran with intracranial bleeding can have the anticoagulant effect of dabigatran rapidly and completely reversed with Idarucizumab.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Bernstein: My presentation is derived from a cohort of the first 90 patients enrolled in reverse-AD. We will publish a similar analysis from the complete reverse ad cohort of 500 patients when we are finished enrolling.
Citation:
International Stroke Conference Oral Abstracts – Session Title: Intracerebral Hemorrhage Oral Abstracts II:Abstract 213: Effect of Idarucizumab on Intracranial Bleeding in Dabigatran-treated Patients: Initial Results From RE-VERSE AD
, , , , , , , , , and
[wysija_form id=”5″]
Richard A. Bernstein MD, PhD (2016). Monoclonal Antibody Idarucizumab Reverses Anticoagulant Effect of Dabigatran In Patients With Brain Bleed MedicalResearch.com
Last Updated on March 4, 2016 by Marie Benz MD FAAD